<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29864">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717923</url>
  </required_header>
  <id_info>
    <org_study_id>TJCC005</org_study_id>
    <nct_id>NCT02717923</nct_id>
  </id_info>
  <brief_title>A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer</brief_title>
  <official_title>Maintenance Treatment With Capecitabine Plus Cetuximab After First-line Modified Fluorouracil, Leucovorin, and Oxaliplatin(mFOLFOX6) Plus Cetuximab for Patients With KRAS Wild-type Metastatic Colorectal Cancer: a Single Arm, Open-label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <brief_summary>
    <textblock>
      This is a single arm, open-label clinical trial to evaluate the efficacy and safety of
      maintenance treatment with capecitabine plus cetuximab after first-line modified
      fluorouracil, leucovorin, and oxaliplatin(mFOLFOX6) plus cetuximab for patients with KRAS
      wild-type metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival of maintaining treatment（mPFS）</measure>
    <time_frame>5 years</time_frame>
    <description>mPFS defined as time from randomisation to progression after maintenance</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Maintenance Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single arm of maintenance treatment with capecitabine plus cetuximab after first-line modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus cetuximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>maintenance treatment with capecitabine plus cetuximab</intervention_name>
    <description>Using a maintenance treatment strategy of capecitabine plus cetuximab as a treatment option in mCRC after first-line mFOLFOX6 plus cetuximab</description>
    <arm_group_label>Maintenance Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects has been fully understand this research and volunteered to sign the consent
             form;

          2. Histologically and/or cytologically diagnosed with KRAS wild-type metastatic
             metastatic colorectal cancer(Phase IV), any other histological type is excluded;

          3. Subjects with stable disease or better after induction treatment with eight to twelve
             2-weekly cycles of mFOLFOX6;

          4. ECOG Performance Status (ECOG PS) ≤1(0-1);

          5. Evident measurable lesion(s) that meets the Response Evaluation Criteria in Solid
             Tumors (RECIST 1.1);

          6. Expected survival＞16 weeks.

        Exclusion Criteria:

          1. Subjects with presence of clinically detectable second primary malignant tumors at
             the enrollment, or other malignant tumors within the last 5 years (excluding
             adequately treated skin basal cell carcinoma or carcinoma in situ of cervix);

          2. Clinical refractory diseases(including uncontrolled epilepsy),and affect survivor;

          3. Central Nervous System (CNS) metastatic disease or prior cerebral metastasis;

          4. Researchers think that the subjects exist any clinical or laboratory abnormalities or
             compliance issues and not suitable to participate in this clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xianglin Yuan, Professional</last_name>
    <phone>13667241722</phone>
    <email>yxl@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ben Zhao, Master</last_name>
    <phone>15071206621</phone>
    <email>zhaoben0609@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianglin Yuan, Professional</last_name>
      <phone>13667241722</phone>
      <email>yxl@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ben Zhao, Master</last_name>
      <phone>15071206621</phone>
      <email>zhaoben0609@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM, Tol J, Braun HJ, Nieboer P, van der Hoeven JJ, Haasjes JG, Jansen RL, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJ, Koopman M. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015 May 9;385(9980):1843-52. doi: 10.1016/S0140-6736(14)62004-3. Epub 2015 Apr 7.</citation>
    <PMID>25862517</PMID>
  </reference>
  <reference>
    <citation>Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015 Oct;16(13):1355-69. doi: 10.1016/S1470-2045(15)00042-X. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589.</citation>
    <PMID>26361971</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 3, 2016</lastchanged_date>
  <firstreceived_date>March 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xianglin Yuan</investigator_full_name>
    <investigator_title>Professor, Chief physician</investigator_title>
  </responsible_party>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>maintenance treatment</keyword>
  <keyword>cetuximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
